Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Dual Targeting of Mitochondrial Unfolded Protein Response and BCL2 in Acute Myeloid Leukemia

Ran Zhao, BS, Sarah Zarabi, MD, Takenobu Nii, PhD, Ondrej Halgas, PhD, Yulia Jitkova, PhD, Vivian Ruvolo, Lauren Heese, Yuki Nishida, MD PhD, Gautam M. Borthakur, MD, Kensuke Kojima, MD PhD, Martin Stogniew, Wolfgang Oster, MD, Emil Pai, PhD, Eric Davis, MD, Hagop M. Kantarjian, MD, Aaron D Schimmer, MD PhD, Michael Andreeff, MD PhD, Jo Ishizawa, MD PhD

Blood (2019) 134 (Supplement_1): 2562.

https://doi.org/10.1182/blood-2019-127101

Published: 2019

Journal Articles

Single Agent and Synergistic Combinatorial Efficacy of First-in-Class Small Molecule Imipridone ONC201 in Hematological Malignancies In Vitro and In Vivo through Apoptosis Via the Integrated Stress Response Pathway

Varun Vijay Prabhu, BPharm, MS, PhD, Mala Kiran Talekar, MD, Amriti R Lulla, MS, C. Leah B Kline, Lanlan Zhou, Junior Hall, A. Pieter J Van den Heuvel, David T Dicker, Stephan A Grupp, MD PhD, Mathew Garnett, Ultan McDermott, Cyril H Benes, Jeffrey J Pu, David F Claxton, MD, Wolfgang Oster, MD, Joshua E. Allen, PhD, Wafik S. El-Deiry

Blood (2017) 130 (Supplement 1): 3842.

https://doi.org/10.1182/blood.V130.Suppl_1.3842.3842

Published: 2017

Journal Articles

The Novel Imipridone ONC212 Induces Pronounced Anti-Leukemia Effects in Vitro and In Vivo and Is Highly Synergistic with the BCL-2 Inhibitor ABT-199

Takenobu Nii, PhD, Jo Ishizawa, MD PhD, Varun Vijay Prabhu, BPharm, MS, PhD, Vivian Ruvolo, PhD, Neel Madhukar, Ran Zhao, Hong Mu, MD PhD, Lauren Heese, Kensuke Kojima, MD PhD, Mathew Garnett, Ultan McDermott, Cyril H Benes, Neil Charter, Sean Deacon, Olivier Elemento, PhD, Joshua E. Allen, PhD, Wolfgang Oster, MD, Martin Stogniew, Michael Andreeff, MD PhD

Blood (2017) 130 (Supplement 1): 2616.

https://doi.org/10.1182/blood.V130.Suppl_1.2616.2616

Published: 2017

Journal Articles

Single Agent and Combinatorial Efficacy of First-in-Class Small Molecule ONC201 in Acute Leukemia and Multiple Myeloma

Varun V Prabhu, PhD, Amriti Lulla, Christina L Kline, PhD, Peter J Van den Heuvel, PhD, Mala K. Talekar, MD, Jessica M Wagner, Rohinton S Tarapore, PhD, David T Dicker, Mathew J Garnett, PhD, Ultan McDermott, MD PhD, Cyril H Benes, PhD, Jeffrey J. Pu, MD PhD, David F. Claxton, MD, Wolfgang Oster, MD PhD, Joshua E Allen, PhD, Wafik S. El-Deiry, MD PhD

Blood (2016) 128 (22): 2759.

https://doi.org/10.1182/blood.V128.22.2759.2759

Published: 2016

Journal Articles

A Phase I/II Clinical Trial of the First-in-Class GPCR Antagonist ONC201 in Relapsed/Refractory Acute Leukemias

Gautam Borthakur, MD, Jo Ishizawa, MD PhD, Courtney D DiNardo, MD, Tapan M. Kadia, MD, Katherine Weise, Joshua E Allen, PhD, Wolfgang Oster, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Michael Andreeff, MD PhD

Blood (2016) 128 (22): 3997.

https://doi.org/10.1182/blood.V128.22.3997.3997

Published: 2016

Journal Articles

Potent Anti-Leukemic Effects of Small Molecule ONC212, a Member of the Imipridone Class of Anti-Cancer Compounds

Varun V Prabhu, PhD, Rohinton S Tarapore, PhD, Mathew J Garnett, PhD, Ultan McDermott, MD PhD, Cyril H Benes, PhD, Jessica M Wagner, Wafik S. El-Deiry, MD PhD, Martin Stogniew, PhD, Wolfgang Oster, MD PhD, Joshua E Allen, PhD

Blood (2016) 128 (22): 5133.

https://doi.org/10.1182/blood.V128.22.5133.5133

Published: 2016

NARROW

Dual Targeting of Mitochondrial Unfolded Protein Response and BCL2 in Acute Myeloid Leukemia

Single Agent and Synergistic Combinatorial Efficacy of First-in-Class Small Molecule Imipridone ONC201 in Hematological Malignancies In Vitro and In Vivo through Apoptosis Via the Integrated Stress Response Pathway

The Novel Imipridone ONC212 Induces Pronounced Anti-Leukemia Effects in Vitro and In Vivo and Is Highly Synergistic with the BCL-2 Inhibitor ABT-199

Single Agent and Combinatorial Efficacy of First-in-Class Small Molecule ONC201 in Acute Leukemia and Multiple Myeloma

A Phase I/II Clinical Trial of the First-in-Class GPCR Antagonist ONC201 in Relapsed/Refractory Acute Leukemias

Potent Anti-Leukemic Effects of Small Molecule ONC212, a Member of the Imipridone Class of Anti-Cancer Compounds

Email alerts

ASH Publications

American Society of Hematology

Dual Targeting of Mitochondrial Unfolded Protein Response and BCL2 in Acute Myeloid Leukemia

Single Agent and Synergistic Combinatorial Efficacy of First-in-Class Small Molecule Imipridone ONC201 in Hematological Malignancies In Vitro and In Vivo through Apoptosis Via the Integrated Stress Response Pathway

The Novel Imipridone ONC212 Induces Pronounced Anti-Leukemia Effects in Vitro and In Vivo and Is Highly Synergistic with the BCL-2 Inhibitor ABT-199

Single Agent and Combinatorial Efficacy of First-in-Class Small Molecule ONC201 in Acute Leukemia and Multiple Myeloma

A Phase I/II Clinical Trial of the First-in-Class GPCR Antagonist ONC201 in Relapsed/Refractory Acute Leukemias

Potent Anti-Leukemic Effects of Small Molecule ONC212, a Member of the Imipridone Class of Anti-Cancer Compounds

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only